检索结果 - Clayton D. Knox

  • Showing 1 - 2 results of 2
Refine Results
  1. 1
    A phase I trial of the human double minute 2 inhibitor (MK-8242) in patients with refractory/recurrent acute myelogenous leukemia (AML)

    A phase I trial of the human double minute 2 inhibitor (MK-8242) in patients with refractory/recurrent acute myelogenous leukemia (AML) 由 Farhad Ravandi, Ivana Gojo, Mrinal M. Patnaik, Mark D. Minden, Hagop M. Kantarjian, Amy O. Johnson‐Levonas, Craig Fancourt, Raymond W. Lam, Mary Jones, Clayton D. Knox, Shelonitda Rose, Payal Patel, Raoul Tibes

    出版 2016
    获取全文
    Artigo
    加到收藏夹
    Saved in:
  2. 2
    Phase I Trial of the Human Double Minute 2 Inhibitor MK-8242 in Patients With Advanced Solid Tumors

    Phase I Trial of the Human Double Minute 2 Inhibitor MK-8242 in Patients With Advanced Solid Tumors 由 Andrew J. Wagner, Udai Banerji, Amit Mahipal, Neeta Somaiah, Heather A. Hirsch, Craig Fancourt, Amy O. Johnson‐Levonas, Raymond W. Lam, Amy Meister, Giuseppe Lo Russo, Clayton D. Knox, Shelonitda Rose, David S. Hong

    出版 2017
    获取全文
    Artigo
    加到收藏夹
    Saved in:

检索工具: